Aspecte imunologice în pronosticul cancerului laringian.
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
918 10
Ultima descărcare din IBN:
2023-06-01 20:15
Căutarea după subiecte
similare conform CZU
616.22-006-036.11-089-092:615.37 (2)
Patologia sistemului respirator. Tulburări ale organelor de respiraţie (747)
Medicamentele potrivit originii lor (470)
SM ISO690:2012
ŢÎBÎRNĂ, Gheorghe, STRATAN, Valentina, BOGDANSCAIA, Nina, DARII, Valentina, CLIPCA, Adrian, DORUC, Andrei, CLIM, Alexandru, MÎNDRUȚA, C., COJOCARU, Corneliu, MARANDIUC, Alexandru, ŢÎBÎRNĂ, Andrei, TARNARUŢCAIA, Rodica. Aspecte imunologice în pronosticul cancerului laringian.. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2018, nr. 2-3(59-60), pp. 8-14. ISSN 1857-0011.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale
Numărul 2-3(59-60) / 2018 / ISSN 1857-0011

Aspecte imunologice în pronosticul cancerului laringian.

Immunological aspects in laryngeal cancer treatment.  

Роль иммунологического статуса в прогнозировании рака гортани.

CZU: 616.22-006-036.11-089-092:615.37

Pag. 8-14

Ţîbîrnă Gheorghe, Stratan Valentina, Bogdanscaia Nina, Darii Valentina, Clipca Adrian, Doruc Andrei, Clim Alexandru, Mîndruța C., Cojocaru Corneliu, Marandiuc Alexandru, Ţîbîrnă Andrei, Tarnaruţcaia Rodica
 
IMSP Institutul Oncologic
 
Disponibil în IBN: 6 ianuarie 2019


Rezumat

Morbiditatea prin cancer laringian în Republica Moldova constituie cca 4,0-4,5 %, anual fiind diagnosticate 140160 cazuri primare de îmbolnăvire. Ponderea bolnavilor depistați în cazuri avansate constituie 75-80%, iar mortalitatea atinge indicii de 1,9-2,2%. În perioada anilor 1980-2017 în Institutul Oncologic au fost trataţi peste 2100 de bolnavi cu cancer laringian stadiile I, IIa, IIb, IIIa, IIIb, IVa. A fost efectuat tratament radioterapeutic, chirurgical, crioterapeutic, lazeroterapie (st. I-II), combinat și complex în diferită succesivitate (st. IIIa-IIIb). Se planifică de a elabora scheme de tratament imunomodulator, fortificând imunitatea prin aplicarea preparatelor imunostimulatoare, ameliorând rezultatele tratamentului la distanță.

The laryngeal cancer morbidity in the Republic of Moldova is 4,0-4,5%, being diagnosed 140-160 of new cases annualy. 75-80% of patients are detected in the late stages and mortality is about 1.9-2.2%. In between 1980 and 2017 in our Institute were treated over 2100 patients with laringeal cancer (stages I, IIa, IIb, IIIa, IIIb, IVa). Patients with st I-II were treated by radiotherapy, surgery, cryotherapyand laser-therapy, and patients with stIIIa-IIIb received combined and complex treatment in different sequences. We plan to establish a new scheme of immunomodulator treatment to enforce the immunity of the body by using immunostimulant drugs in order to achieve better results of the treatment at the distance

Заболеваемость раком гортани в Республике Молдова составляет 4,0-4,5%. Ежегодно диагностируются 140-160 первичных больных. Число больных выявленных в запущенных стадиях составляет 75-80%, а смертность достигает уровня 1,9-2,2%. В период 1980-2017 в Институте Онкологии лечились больше 2100 больных раком гортани в стадиях: I, IIa, IIb, IIIa, IIIb, IVа. Было проведено: радиотерапия, хирургическое лечение, криотерапия, лазеротерапия (в ст. I-II) и комбинированное лечение в различной последовательности лучевого, хирургического компонентов (в ст. IIIa-IIIb). Будут выработаны схемы имуномодулярного лечения, стимулируя имунитет с помощью имунопрепаратов, улучшая отдаленные результаты лечения.   

Cuvinte-cheie
cancer laringian, rezecţie de laringe, laringectomii, tratament combinat, complex, radioterapie, imunoterapie.

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'>
<creators>
<creator>
<creatorName>Ţîbîrnă, G.A.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Stratan, V.G.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Bogdanscaia, N.I.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Darii, V.A.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Clipca, A.I.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Doruc, A.S.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Clim, A.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Mîndruța, C.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Cojocaru, C.D.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Marandiuc, A.S.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Ţîbîrnă, A.G.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Tarnaruţcaia, R.V.</creatorName>
<affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation>
</creator>
</creators>
<titles>
<title xml:lang='ro'>Aspecte imunologice &icirc;n pronosticul cancerului laringian.</title>
</titles>
<publisher>Instrumentul Bibliometric National</publisher>
<publicationYear>2018</publicationYear>
<relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1857-0011</relatedIdentifier>
<subjects>
<subject>cancer laringian</subject>
<subject>rezecţie de laringe</subject>
<subject>laringectomii</subject>
<subject>tratament combinat</subject>
<subject>complex</subject>
<subject>radioterapie</subject>
<subject>imunoterapie.</subject>
<subject schemeURI='http://udcdata.info/' subjectScheme='UDC'>616.22-006-036.11-089-092:615.37</subject>
</subjects>
<dates>
<date dateType='Issued'>2018-12-25</date>
</dates>
<resourceType resourceTypeGeneral='Text'>Journal article</resourceType>
<descriptions>
<description xml:lang='ro' descriptionType='Abstract'><p>Morbiditatea prin cancer laringian &icirc;n Republica Moldova constituie cca 4,0-4,5 %, anual fiind diagnosticate 140160 cazuri primare de &icirc;mbolnăvire. Ponderea bolnavilor depistați &icirc;n cazuri avansate constituie 75-80%, iar mortalitatea atinge indicii de 1,9-2,2%. &Icirc;n perioada anilor 1980-2017 &icirc;n Institutul Oncologic au fost trataţi peste 2100 de bolnavi cu cancer laringian stadiile I, IIa, IIb, IIIa, IIIb, IVa. A fost efectuat tratament radioterapeutic, chirurgical, crioterapeutic, lazeroterapie (st. I-II), combinat și complex &icirc;n diferită succesivitate (st. IIIa-IIIb). Se planifică de a elabora scheme de tratament imunomodulator, fortific&acirc;nd imunitatea prin aplicarea preparatelor imunostimulatoare, amelior&acirc;nd rezultatele tratamentului la distanță.</p></description>
<description xml:lang='en' descriptionType='Abstract'><p>The laryngeal cancer morbidity in the Republic of Moldova is 4,0-4,5%, being diagnosed 140-160 of new cases annualy. 75-80% of patients are detected in the late stages and mortality is about 1.9-2.2%. In between 1980 and 2017 in our Institute were treated over 2100 patients with laringeal cancer (stages I, IIa, IIb, IIIa, IIIb, IVa). Patients with st I-II were treated by radiotherapy, surgery, cryotherapyand laser-therapy, and patients with stIIIa-IIIb received combined and complex treatment in different sequences. We plan to establish a new scheme of immunomodulator treatment to enforce the immunity of the body by using immunostimulant drugs in order to achieve better results of the treatment at the distance</p></description>
<description xml:lang='ru' descriptionType='Abstract'><p>Заболеваемость раком гортани в Республике Молдова составляет 4,0-4,5%. Ежегодно диагностируются 140-160 первичных больных. Число больных выявленных в запущенных стадиях составляет 75-80%, а смертность достигает уровня 1,9-2,2%. В период 1980-2017 в Институте Онкологии лечились больше 2100 больных раком гортани в стадиях: I, IIa, IIb, IIIa, IIIb, IVа. Было проведено: радиотерапия, хирургическое лечение, криотерапия, лазеротерапия (в ст. I-II) и комбинированное лечение в различной последовательности лучевого, хирургического компонентов (в ст. IIIa-IIIb). Будут выработаны схемы имуномодулярного лечения, стимулируя имунитет с помощью имунопрепаратов, улучшая отдаленные результаты лечения. &nbsp;&nbsp;</p></description>
</descriptions>
<formats>
<format>application/pdf</format>
</formats>
</resource>